INNOVATION MODELS IN THE BIOPHARMACEUTICAL SECTOR - Innovation in the Biopharmaceutical Industry - page 27

Kings Fund (2006). Local Variations in NHS Spending Priorities —Briefing Paper , August,
at http://www.kingsfund.org.uk.
Landau, R, D Achilladelis and A Scriabine (1999). Pharmaceutical Innovation — Revolu-
tionising Human Health . Philadelphia, USA: Chemical Heritage Press.
Laursen, K (1997). Horizontal diversification in the Danish national system of innovation:
the case of pharmaceuticals. Research Policy , 25, 1121.
Lerner, J and R Meyers (1998). The control of technology alliances: an empirical analysis
of the biotechnology industry. The Journal of Industrial Economics , XLVI, 125.
Levin, RC, AK Klevonick, RR Nelson and SG Winter (1987). Appropriating the returns
from industrial R&D. Brookings Papers on Economic Activity , 3, 794.
Lichtenberg, FR (2005). Pharmaceutical knowledge-capital accumulation and longevity. In
Measuring Capital in the NewEconomy , C Corrado, J Haltiwanger and D Sichrl (eds.).
Chicago, USA: University of Chicago.
Mansfield, E (1986). Patents and innovation: an empirical study. Management Science , 175.
Mansfield, E (1989). The diffusion of industrial robots in Japan and the US, Research Policy ,
15, 193.
McKelvey, M, H Alm and M Riccaboni (2003). Does co-location matter for formal knowl-
edge collaboration in the Swedish biotechnology-pharmaceutical sector? Research
Policy , 32, 483.
Morgan, SG, KL Bassett, JM Wright, RG Evans, ML Barer, PL Caetano and CD Black
(2005). Breakthrough drugs and growth in expenditure on prescription drugs in Canada.
British Medical Journal , 331, 815-816.
Mowbery, DC and N Rosenberg (1979). The influence of market demand on innovation: a
critical review of some recent empirical studies. Research Policy , 8(1).
Mueller, DC (1986). Profits in the Long Run , pp. 11-42. Cambridge, UK: Cambridge
University Press.
Myers, S (1999). Measuring pharmaceutical risk and the cost of capital. In Risk and Return
in the Pharmaceutical Industry , J Sussex and N Marchant (eds.). London: OHE.
Nelson, R (ed.) (1993). National Innovation Systems . Oxford: Oxford University Press.
Nelson, RR and SG Winter (1982). An Evolutionary Theory of Economic Change .
Cambridge, MA: Bellnap Press.
Nelson, RR and SG Winter (1997). In search of a useful theory of innovation. Research
Policy , 6(36).
Nicholls-Nixon, CL and CY Woo (2003). Technology souring and the output of established
firms in a regime encompassing technological change. StrategicManagement Journal ,
24, 651-666.
Nightingale, P and P Martin (2004). The myth of the biotech revolution. Trends in Biotech-
nology , 22, 564.
OECD (2006). Innovation in Pharmaceutical Biotechnology: Comparing National Inno-
vation Systems at the Sectoral Level .Paris,France:OECD.AvailableatURL:
www.oecd.org/sti/innovation.
Orsenigo, L, F Pammolli and M Riccaboni (2001). Technological change and network
dynamics: lessons from the pharmaceutical industry. Research Policy , 30, 485-508.